ESMO 2019 | CRT and Debio1143 for treatment of LA SCCHN

Jean Bourhis

Jean Bourhis, MD, PhD, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland outlines the initial findings in this double-blind randomized phase II trial regarding the use of cisplatin chemoradiation (CRT) plus debio 1143 in the treatment of locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  
Similar topics
Related videos
1:21
REACH safety data: avelumab plus RT-cetuximab in LA SCCHN
Jean Bourhis
1:02
NPC communication between the West and China
Ming-Yuan Chen
2:22
Phase III trial: chemotherapy plus local-regional radiotherapy in pmNPCC
Ming-Yuan Chen
1:48
Pharmacy perspective: pembrolizumab monotherapy 6 weekly dosing
Rob Duncombe
2:13
The value of PD-L1 as a biomarker beyond lung cancers
Kevin Harrington
Head and Neck Cancer
Cisplatin
ESMO 2019
Interview
27th September 2019
More from Jean Bourhis
REACH safety data: avelumab plus RT-cetuximab in LA SCCHN
vjoncology logo VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals